Therapeutic effects of T-type and N-type calcium channel blockers on hypertensive diabetic patients with renal diseases. (TITANS Study)

Therapeutic effects of T-type and N-type calcium channel blockers on hypertensive diabetic patients with renal diseases. (TITANS Study) - Therapeutic effects of T-type and N-type calcium channel blockers on hypertensive diabetic patients with renal diseases. (TITANS Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003574

Enrollment

Registered

2010-05-06

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive diabetic patients with renal diseases

Interventions

Group A: Change already prescribed L-type calcium channel blockers to daily dosing of benidipine 8 mg daily for 24 weeks, and dosage may be modulated accroding to the clinical parameters. After benidi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive diabetic patients with renal diseases, who are not treaeted with L/T type nor L/N type calcium channel blockers 1. Albuminuria is over 30 mg/gCr. 2. Type 2 diabates who were diagnosed by criteria of Japan Diabetes Society. 3. SBP>=140 mmHg or DBP>=90 mmHg, or patients who are already treated with antihyperteisive agents.

Exclusion criteria

Exclusion criteria: 1. Patients who are contraindicated to benidipine or cilnidipine. 2. Patients without imformed consent. 3. Inappropriate patients based on the descision by responsible doctors.

Design outcomes

Primary

Measure	Time frame
1.Clinic blood pressure, pulse rate 2.Blood test; K+, Cr, NE, aldosterone, ACTH, cortisol, BNP 3.Urine test; albuminuria 4.Vascular test; PWV, AI	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026